Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

EZETIMIBE 10 MG TABLET

ezetimibe
$0.0724per EA

Strength

10 mg/1

Manufacturer

Quallent Pharmaceuticals Health LLC

NDC

82009002405

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

EZETIMIBE

Approval Type

Generic (ANDA)

FDA Application

ANDA204331

On Market Since

8/20/2022

Pharmacological Classes

Decreased Cholesterol Absorption
Dietary Cholesterol Absorption Inhibitor

Price History

1W

0.0%

1M

-0.2%

3M

-4.3%

6M

+5.3%

1Y

-4.7%

3Y

-18.7%

5Y

N/A

All

-29.7%

Generic Alternatives

1 alternative • Same active ingredient

EZETIMIBE 10 MG TABLET
Generic
68382077306•Zydus Pharmaceuticals (USA) Inc.
$0.0724

Related Drugs

Same classification

EZETIMIBE 10 MG TABLET
Generic
00591371305•Actavis Pharma, Inc.
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
00591371319•Actavis Pharma, Inc.
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
00591371330•Actavis Pharma, Inc.
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
00904710304•Major Pharmaceuticals
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
00904710310•Major Pharmaceuticals
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
16714081301•NorthStar Rx LLC
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
16714081302•NorthStar Rx LLC
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
16714081303•NorthStar Rx LLC
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
16729043310•Accord Healthcare Inc.
$0.0724
per EA
EZETIMIBE 10 MG TABLET
Generic
31722062805•Camber Pharmaceuticals Inc.
$0.0724
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy